351 related articles for article (PubMed ID: 31952903)
1. MUCIN-4 (MUC4) is a novel tumor antigen in pancreatic cancer immunotherapy.
Gautam SK; Kumar S; Dam V; Ghersi D; Jain M; Batra SK
Semin Immunol; 2020 Feb; 47():101391. PubMed ID: 31952903
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
Amedei A; Niccolai E; Prisco D
Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic cancer counterattack: MUC4 mediates Fas-independent apoptosis of antigen-specific cytotoxic T lymphocyte.
Zhu Y; Zhang JJ; Liang WB; Zhu R; Wang B; Miao Y; Xu ZK
Oncol Rep; 2014 Apr; 31(4):1768-76. PubMed ID: 24534824
[TBL] [Abstract][Full Text] [Related]
4. MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma.
Gautam SK; Kumar S; Cannon A; Hall B; Bhatia R; Nasser MW; Mahapatra S; Batra SK; Jain M
Expert Opin Ther Targets; 2017 Jul; 21(7):657-669. PubMed ID: 28460571
[TBL] [Abstract][Full Text] [Related]
5. Generation of CTL responses against pancreatic cancer in vitro using dendritic cells co-transfected with MUC4 and survivin RNA.
Chen J; Guo XZ; Li HY; Liu X; Ren LN; Wang D; Zhao JJ
Vaccine; 2013 Sep; 31(41):4585-90. PubMed ID: 23928463
[TBL] [Abstract][Full Text] [Related]
6. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
7. Antibody induction directed against the tumor-associated MUC4 glycoprotein.
Cai H; Palitzsch B; Hartmann S; Stergiou N; Kunz H; Schmitt E; Westerlind U
Chembiochem; 2015 Apr; 16(6):959-67. PubMed ID: 25755023
[TBL] [Abstract][Full Text] [Related]
8. Axed MUC4 (MUC4/X) aggravates pancreatic malignant phenotype by activating integrin-β1/FAK/ERK pathway.
Jahan R; Macha MA; Rachagani S; Das S; Smith LM; Kaur S; Batra SK
Biochim Biophys Acta Mol Basis Dis; 2018 Aug; 1864(8):2538-2549. PubMed ID: 29777904
[TBL] [Abstract][Full Text] [Related]
9. A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.
Chen Z; Zhang S; Han N; Jiang J; Xu Y; Ma D; Lu L; Guo X; Qiu M; Huang Q; Wang H; Mo F; Chen S; Yang L
Front Immunol; 2021; 12():691605. PubMed ID: 34484187
[TBL] [Abstract][Full Text] [Related]
10. Identification of an HLA-A*0201-restrictive CTL epitope from MUC4 for applicable vaccine therapy.
Wu J; Wei J; Meng K; Chen J; Gao W; Zhang J; Xu Z; Miao Y
Immunopharmacol Immunotoxicol; 2009; 31(3):468-76. PubMed ID: 19555216
[TBL] [Abstract][Full Text] [Related]
11. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
[TBL] [Abstract][Full Text] [Related]
12. Emerging trends in the immunotherapy of pancreatic cancer.
Banerjee K; Kumar S; Ross KA; Gautam S; Poelaert B; Nasser MW; Aithal A; Bhatia R; Wannemuehler MJ; Narasimhan B; Solheim JC; Batra SK; Jain M
Cancer Lett; 2018 Mar; 417():35-46. PubMed ID: 29242097
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies recognizing the non-tandem repeat regions of the human mucin MUC4 in pancreatic cancer.
Jain M; Venkatraman G; Moniaux N; Kaur S; Kumar S; Chakraborty S; Varshney GC; Batra SK
PLoS One; 2011; 6(8):e23344. PubMed ID: 21886786
[TBL] [Abstract][Full Text] [Related]
14. Nicotine/cigarette smoke promotes metastasis of pancreatic cancer through α7nAChR-mediated MUC4 upregulation.
Momi N; Ponnusamy MP; Kaur S; Rachagani S; Kunigal SS; Chellappan S; Ouellette MM; Batra SK
Oncogene; 2013 Mar; 32(11):1384-95. PubMed ID: 22614008
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineered to express α-gal epitopes, targets pancreatic cancer stem cells.
Tanida T; Tanemura M; Miyoshi E; Nagano H; Furukawa K; Nonaka Y; Akita H; Hama N; Wada H; Kawamoto K; Kobayashi S; Eguchi H; Mori M; Doki Y
Int J Oncol; 2015 Jan; 46(1):78-90. PubMed ID: 25354268
[TBL] [Abstract][Full Text] [Related]
16. Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer.
Kinkead HL; Hopkins A; Lutz E; Wu AA; Yarchoan M; Cruz K; Woolman S; Vithayathil T; Glickman LH; Ndubaku CO; McWhirter SM; Dubensky TW; Armstrong TD; Jaffee EM; Zaidi N
JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333318
[TBL] [Abstract][Full Text] [Related]
17. The role of the AMOP domain in MUC4/Y-promoted tumour angiogenesis and metastasis in pancreatic cancer.
Tang J; Zhu Y; Xie K; Zhang X; Zhi X; Wang W; Li Z; Zhang Q; Wang L; Wang J; Xu Z
J Exp Clin Cancer Res; 2016 Jun; 35(1):91. PubMed ID: 27287498
[TBL] [Abstract][Full Text] [Related]
18. Immunoprevention of Pancreatic Cancer.
Rao CV; Mohammed A; Asch AS; Janakiram NB
Curr Med Chem; 2018; 25(22):2576-2584. PubMed ID: 28240168
[TBL] [Abstract][Full Text] [Related]
19. Role of MUC4-NIDO domain in the MUC4-mediated metastasis of pancreatic cancer cells.
Senapati S; Gnanapragassam VS; Moniaux N; Momi N; Batra SK
Oncogene; 2012 Jul; 31(28):3346-56. PubMed ID: 22105367
[TBL] [Abstract][Full Text] [Related]
20. Polyanhydride nanoparticles stabilize pancreatic cancer antigen MUC4β.
Liu L; Kshirsagar P; Christiansen J; Gautam SK; Aithal A; Gulati M; Kumar S; Solheim JC; Batra SK; Jain M; Wannemuehler MJ; Narasimhan B
J Biomed Mater Res A; 2021 Jun; 109(6):893-902. PubMed ID: 32776461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
